Global coronavirus cases exceeded 10 million on Sunday according to a Reuters tally, marking a major milestone in the spread of the respiratory disease that has so far killed almost half a million people in seven months.

Many studies assessing the accuracy of COVID-19 antibody tests had major shortcomings, a review concluded, offering further evidence the blood tests are of little use for people seeking to know with certainty if they have been infected.

As AstraZeneca closes in on developing a vaccine against COVID-19, the U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020.

AstraZeneca Plc signed a contract with European governments to supply the region with a potential vaccine against the coronavirus, the British drugmaker’s latest deal to pledge the company’s drug to help combat the pandemic.

The European health regulator is looking to fast-track approval of Gilead’s antiviral remdesivir as a potential COVID-19 treatment in Europe.

The U.S. Food and Drug Administration extended the review period for Novartis AG’s multiple sclerosis drug ofatumumab by three months.

Sanofi temporarily stopped recruiting new COVID-19 patients for two clinical trials on hydroxychloroquine and will no longer supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up.

Global coronavirus cases surpassed 5 million, with Latin America overtaking the United States and Europe in the past week to report the largest portion of new daily cases globally.

The Centers for Disease Control and Prevention (CDC) is on the cusp of launching a massive, 25-city SARS-CoV-2 antibody study.

Randall Bolten – longtime Silicon Valley CFO, UC Berkeley Professor and author of the book Painting with Numbers: Presenting Financials and Other Numbers So People Will Understand You – released a research note on updated COVID-19 testing numbers. Broken down by country through May 10, 2020, the United States is not near the top of the pack.